Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LPAR3 | Q9UBY5 | 11/20 | 0.45 |
| ▸ | LPAR2 | Q9HBW0 | 9/20 | 0.45 |
| ▸ | LPAR1 | Q92633 | 4/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.41 |
| ▸ | PLA2G2A | P14555 | 4/20 | 0.37 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | BTN3A1 | O00481 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15935828 | 0.98 | LPAR3 (0.48) | LPAR3LPAR2LPAR1ALDH1A1PLA2G2A | |
| SCHEMBL10178024 | 0.98 | LPAR3 (0.48) | LPAR3LPAR2LPAR1ALDH1A1PLA2G2A | |
| SCHEMBL9999834 | 0.95 | LPAR3 (0.40) | LPAR3LPAR2LPAR1ALDH1A1PLA2G2A | |
| SCHEMBL19699811 | 0.90 | LPAR3 (0.43) | LPAR3LPAR2LPAR1PLA2G2ACYP3A4 | |
| SCHEMBL18917021 | 0.88 | LPAR3 (0.59) | LPAR3LPAR2LPAR1PLA2G2ABTN3A1 | |
| SCHEMBL13912179 | 0.87 | SAT1 (0.49) | LPAR3LPAR2LPAR1ALDH1A1PLA2G2A | |
| SCHEMBL26757374 | 0.87 | LPAR3 (0.40) | LPAR3LPAR2LPAR1ALDH1A1PLA2G2A | |
| SCHEMBL3824229 | 0.86 | LPAR3 (0.63) | LPAR3LPAR2LPAR1PLA2G2ACYP3A4 | |
| SCHEMBL14614344 | 0.86 | LPAR3 (0.42) | LPAR3LPAR2LPAR1PLA2G2ACYP3A4 | |
| SCHEMBL6352756 | 0.85 | BTN3A1 (0.38) | LPAR3LPAR2LPAR1ALDH1A1PLA2G2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20150011001-A1 | COMPOSITIONS AND METHODS FOR OPTIMIZING CLEAVAGE OF RNA BY RNASE H | ISIS PHARMACEUTICALS, INC. (US) | 2015-01-08 | — | — | US | disclosed |
| US-20140220573-A1 | EMBODIMENTS OF A PROBE AND METHOD FOR TARGETING NUCLEIC ACIDS | UNIVERSITY OF IDAHO (US) | 2014-08-07 | — | — | US | disclosed |
| US-8790919-B2 | Compositions and methods for optimizing cleavage of RNA by RNase H | ISIS PHARMACEUTICALS, INC. (US) | 2014-07-29 | — | — | US | disclosed |
| EP-2700720-A2 | Compositions and methods for optimizing cleavage of RNA by RNASE H | Isis Pharmaceuticals, Inc. (US) | 2014-02-26 | — | — | EP | disclosed |
| US-20120156138-A1 | Methods and Compositions for the Treatment of Medical Conditions Involving Cellular Reprogramming | SMITH LARRY J (US) | 2012-06-21 | — | — | US | disclosed |
| US-20080207541-A1 | Contacting a eukaryotic cell with a mixed backbone oligonucleotide with a first region that forms a substrate for cleavage by an RNase and a second region which does not, and a transition moiety which modulates the transmission of the conformation of said second region into the first region | IONIS PHARMACEUTICALS, INC. | 2008-08-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080207541-A1 | Contacting a eukaryotic cell with a mixed backbone oligonucleotide with a first region that forms a substrate for cleavage by an RNase and a second region which does not, and a transition moiety which modulates the transmission of the conformation of said second region into the first region | RNASEH1, NSUN3, RNASEL | LPAR3 1368/4885LPAR2 2716/4885LPAR1 2705/4885 |
| US-20120156138-A1 | Methods and Compositions for the Treatment of Medical Conditions Involving Cellular Reprogramming | CKMT1A; CKMT1B, ATF4, NFATC1 | LPAR3 629/4885LPAR2 484/4885LPAR1 674/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.